Cargando…

A Tissue Engineering Approach to Metastatic Colon Cancer

Colon cancer remains the third most common cause of cancer in the US, and the third most common cause of cancer death. Worldwide, colon cancer is the second most common cause of cancer and cancer deaths. At least 25% of patients still present with metastatic disease, and at least 25-30% will develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarvestani, Samaneh Kamali, DeHaan, Reece K., Miller, Paula G., Bose, Shree, Shen, Xiling, Shuler, Michael L., Huang, Emina H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653071/
https://www.ncbi.nlm.nih.gov/pubmed/33205026
http://dx.doi.org/10.1016/j.isci.2020.101719
_version_ 1783607825899978752
author Sarvestani, Samaneh Kamali
DeHaan, Reece K.
Miller, Paula G.
Bose, Shree
Shen, Xiling
Shuler, Michael L.
Huang, Emina H.
author_facet Sarvestani, Samaneh Kamali
DeHaan, Reece K.
Miller, Paula G.
Bose, Shree
Shen, Xiling
Shuler, Michael L.
Huang, Emina H.
author_sort Sarvestani, Samaneh Kamali
collection PubMed
description Colon cancer remains the third most common cause of cancer in the US, and the third most common cause of cancer death. Worldwide, colon cancer is the second most common cause of cancer and cancer deaths. At least 25% of patients still present with metastatic disease, and at least 25-30% will develop metastatic colon cancer in the course of their disease. While chemotherapy and surgery remain the mainstay of treatment, understanding the fundamental cellular niche and mechanical properties that result in metastases would facilitate both prevention and cure. Advances in biomaterials, novel 3D primary human cells, modelling using microfluidics and the ability to alter the physical environment, now offers a unique opportunity to develop and test impactful treatment.
format Online
Article
Text
id pubmed-7653071
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-76530712020-11-16 A Tissue Engineering Approach to Metastatic Colon Cancer Sarvestani, Samaneh Kamali DeHaan, Reece K. Miller, Paula G. Bose, Shree Shen, Xiling Shuler, Michael L. Huang, Emina H. iScience Review Colon cancer remains the third most common cause of cancer in the US, and the third most common cause of cancer death. Worldwide, colon cancer is the second most common cause of cancer and cancer deaths. At least 25% of patients still present with metastatic disease, and at least 25-30% will develop metastatic colon cancer in the course of their disease. While chemotherapy and surgery remain the mainstay of treatment, understanding the fundamental cellular niche and mechanical properties that result in metastases would facilitate both prevention and cure. Advances in biomaterials, novel 3D primary human cells, modelling using microfluidics and the ability to alter the physical environment, now offers a unique opportunity to develop and test impactful treatment. Elsevier 2020-10-20 /pmc/articles/PMC7653071/ /pubmed/33205026 http://dx.doi.org/10.1016/j.isci.2020.101719 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Sarvestani, Samaneh Kamali
DeHaan, Reece K.
Miller, Paula G.
Bose, Shree
Shen, Xiling
Shuler, Michael L.
Huang, Emina H.
A Tissue Engineering Approach to Metastatic Colon Cancer
title A Tissue Engineering Approach to Metastatic Colon Cancer
title_full A Tissue Engineering Approach to Metastatic Colon Cancer
title_fullStr A Tissue Engineering Approach to Metastatic Colon Cancer
title_full_unstemmed A Tissue Engineering Approach to Metastatic Colon Cancer
title_short A Tissue Engineering Approach to Metastatic Colon Cancer
title_sort tissue engineering approach to metastatic colon cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653071/
https://www.ncbi.nlm.nih.gov/pubmed/33205026
http://dx.doi.org/10.1016/j.isci.2020.101719
work_keys_str_mv AT sarvestanisamanehkamali atissueengineeringapproachtometastaticcoloncancer
AT dehaanreecek atissueengineeringapproachtometastaticcoloncancer
AT millerpaulag atissueengineeringapproachtometastaticcoloncancer
AT boseshree atissueengineeringapproachtometastaticcoloncancer
AT shenxiling atissueengineeringapproachtometastaticcoloncancer
AT shulermichaell atissueengineeringapproachtometastaticcoloncancer
AT huangeminah atissueengineeringapproachtometastaticcoloncancer
AT sarvestanisamanehkamali tissueengineeringapproachtometastaticcoloncancer
AT dehaanreecek tissueengineeringapproachtometastaticcoloncancer
AT millerpaulag tissueengineeringapproachtometastaticcoloncancer
AT boseshree tissueengineeringapproachtometastaticcoloncancer
AT shenxiling tissueengineeringapproachtometastaticcoloncancer
AT shulermichaell tissueengineeringapproachtometastaticcoloncancer
AT huangeminah tissueengineeringapproachtometastaticcoloncancer